Redeye: Absolent - Softer near-term outlook
Redeye is making some downward revisions to our near-term forecasts on the back of softer Q3 numbers and outlook. Lower top-line and a negative sales mix weighed on earnings and margins. Still, Absolent posted EBITDA margins of 17% demonstrating good resilience. Our valuation is now lower, mainly due to rating changes and a higher WACC.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/